These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
407 related articles for article (PubMed ID: 31738427)
21. Neurotrophic tyrosine receptor kinase fusion in pediatric central nervous system tumors. Lang SS; Kumar NK; Madsen P; Gajjar AA; Gajjar E; Resnick AC; Storm PB Cancer Genet; 2022 Apr; 262-263():64-70. PubMed ID: 35108662 [TBL] [Abstract][Full Text] [Related]
22. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas. Kummar S; Shen L; Hong DS; McDermott R; Keedy VL; Casanova M; Demetri GD; Dowlati A; Melcón SG; Lassen UN; Leyvraz S; Liu T; Moreno V; Patel J; Patil T; Mallick AB; Sousa N; Tahara M; Ziegler DS; Norenberg R; Arvis P; Brega N; Drilon A; Tan DSW Cancer; 2023 Dec; 129(23):3772-3782. PubMed ID: 37769113 [TBL] [Abstract][Full Text] [Related]
23. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing. Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853 [TBL] [Abstract][Full Text] [Related]
24. NTRK fusions in thyroid cancer: Pathology and clinical aspects. Ma Y; Zhang Q; Zhang K; Liang Y; Ren F; Zhang J; Kan C; Han F; Sun X Crit Rev Oncol Hematol; 2023 Apr; 184():103957. PubMed ID: 36907364 [TBL] [Abstract][Full Text] [Related]
25. Nefarious NTRK oncogenic fusions in pediatric sarcomas: Too many to Trk. Aepala MR; Peiris MN; Jiang Z; Yang W; Meyer AN; Donoghue DJ Cytokine Growth Factor Rev; 2022 Dec; 68():93-106. PubMed ID: 36153202 [TBL] [Abstract][Full Text] [Related]
26. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes. Bautista-Wong C; Mojica-González Z; Hop-Garcia K; Bornstein Quevedo L Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):213-216. PubMed ID: 37017998 [TBL] [Abstract][Full Text] [Related]
27. TRK inhibitors in TRK fusion-positive cancers. Drilon A Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935 [TBL] [Abstract][Full Text] [Related]
28. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment. Qi C; Zhou T; Bai Y; Chen H; Yuan J; Zhao F; Liu C; Ma M; Bei T; Chen S; Zhao X; Chen C; Shen L Int J Cancer; 2023 Dec; 153(11):1916-1927. PubMed ID: 36946696 [TBL] [Abstract][Full Text] [Related]
29. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients. Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351 [TBL] [Abstract][Full Text] [Related]
30. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis. Hondelink LM; Schrader AMR; Asri Aghmuni G; Solleveld-Westerink N; Cleton-Jansen AM; van Egmond D; Boot A; Ouahoud S; Khalifa MN; Wai Lam S; Morreau H; Bovee JVMG; van Wezel T; Cohen D Eur J Cancer; 2022 Sep; 173():229-237. PubMed ID: 35933886 [TBL] [Abstract][Full Text] [Related]
31. [NTRK Gene Fusions and Treatment in NTRK Fusion-Positive Solid Cancers]. Fukuda M; Naito Y Gan To Kagaku Ryoho; 2022 Oct; 49(10):1048-1050. PubMed ID: 36281593 [TBL] [Abstract][Full Text] [Related]
32. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586 [TBL] [Abstract][Full Text] [Related]